Am I missing something. What's Decibel done that been encouraging?At long last! Finally an update from Decibel Tx. Well worth the wait I would say. They are generally not as vocal as Frequency Tx, but when they post a press release they usually slam it down big time.
They have gathered some of the best scientists in the world in their respective area of expertise, and they have some of the largest industrial and venture capital partners on board. All with the purpose of better understanding and treating hearing loss and hearing disorders.Am I missing something. What's Decibel done that been encouraging?
They are not looking for a quick fix. They are out to get to the bottom of the problem and find a long-lasting solution. For that, they have to do some heavy lifting.I still don't have a clue as to what they're using all this money for.
I think we are all assuming these venture capitalists know what they are doing which should not be a given.We may not see the fruits of these activities for a long time. But I think it's safe to say that we can expect something substantial from Decibel Tx in the future.
Right... they don't know what they're doing, but you do? No one knows for sure what the future will bring. The best way to predict the future is to invent it. But innovation costs money. You can be the next Tesla, but if you don't have the money and someone to financially support you and your high-flying ideas, you won't succeed.I think we are all assuming these venture capitalists know what they are doing which should not be a given.
I could see Decibel in 4 year smugly pitching some very narrow gene therapy that is only effect in very early inutero development and otoprotectives that only work if taken within milliseconds of a noise event. These will have such narrow applications as to be moot when talking about therapies.
Just cause they are spending lots of money doesn't necessarily mean they are learning anything of value.
This is venture capital. Big Risk, but a big payout if it pans out. Many of these companies go under with nothing to show. This is probably less of a gamble than many of the other startup companies though which is why it has been so heavily invested. I think they are looking long term, taking it slowly and trying to make it a successful company. Everyone keeps saying a cure to hearing loss is possible, it just that no one knows exactly when it will happen.I think we are all assuming these venture capitalists know what they are doing which should not be a given.
I could see Decibel in 4 year smugly pitching some very narrow gene therapy that is only effect in very early inutero development and otoprotectives that only work if taken within milliseconds of a noise event. These will have such narrow applications as to be moot when talking about therapies.
Just cause they are spending lots of money doesn't necessarily mean they are learning anything of value.
An additional 55 million is very impressive, but that money can go quickly if you are not careful and spend the money unwisely. It seems like they have a lot of seasoned veterans on their team, who have been through this many times before, and understand what it takes to make a company successful.
Decibel has two compounds for hearing protection, one an oral formulation and a second that is administered locally to the ear. One of the drugs was developed to prevent hearing loss in cancer patients receiving cisplatin treatment. Those patients lose hearing because chemotherapy kills cells involved in the process of hearing as well as cancer cells, Holtzman says. In preclinical studies, the drug protected hearing in mice. Decibel administered the drug to one ear while leaving the other ear untreated—making the mouse's own untreated ear the control in the experiment. In the tests, "the unprotected ear has severe hearing loss and the drugged ear is protected 100 percent of the time," Holtzman says.
The company is also developing drugs to restore hearing. In 80 percent of the cases where a newborn has hearing loss, the cause is genetic, Holtzman says. Decibel is working on gene therapies to correct genetic defects. Holtzman says Decibel is pursuing a number of potential gene therapies, and the company expects to select candidates for clinical testing in the first half of next year. Clinical trials could begin by early 2020.
Holtzman says the hearing loss that comes with age is not a loss of volume, it's the diminished ability to distinguish one sound from another, such as voices in restaurants and other noisy environments. Decibel scientists have found that this type of hearing loss is the result of damage to the sensory nerves of the ear, he adds.
Decibel and Regeneron are working together to develop drugs that treat this nerve damage. The partnership, which began last fall, covers multiple drug candidates, including gene therapies, and includes conditions such as tinnitus, the perception of ringing or other noise in one or both ears.
This is amazing news.Two compounds for hearing protection.
And a gene therapy to restore hearing.
They seem to be targeting hidden hearing loss or synaptopathy.
Source:
https://www.xconomy.com/boston/2018...o-bring-multiple-hearing-drugs-to-the-clinic/
This gives my weary soul a bit of hope. Knowing the historical pace of scientific research I can only hope I'm truly not being overly optimistic.Two compounds for hearing protection.
And a gene therapy to restore hearing.
They seem to be targeting hidden hearing loss or synaptopathy.
Source:
https://www.xconomy.com/boston/2018...o-bring-multiple-hearing-drugs-to-the-clinic/